Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500629 · ClinicalTrials.gov registry record · Early Phase 1
Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
A Early Phase 1 study, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT01500629: Completed Early Phase 1 study, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC.
NCT01500629 is a Early Phase 1 study that has completed, run by McNeil Consumer Healthcare Division of McNEIL-PPC. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01500629, a Early Phase 1 study, has completed, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a new nasal spray can reduce the signs and symptoms of allergic rhinitis (hayfever). Subjects' participation in the study will last approximately 4 to 6 weeks, and each of three study visits during that time will last a few hours. Subjects will be required to have several tests done including allergy and breathing tests. They will be exposed to the item they are allergic to and will have small paper discs put in their noses. Subjects will also have the inside of their noses examined and will be asked questions about the level of their allergy symptoms.
Interventions
- DEVICE C-1266-7
- DEVICE C-1266-6 (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500629
The ClinicalTrials.gov registry entry for NCT01500629 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McNeil Consumer Healthcare Division of McNEIL-PPC, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which C-1266-7 is the first listed.
NCT01500629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01500629 about?
NCT01500629 is a clinical study titled "Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever". The purpose of this study is to see if a new nasal spray can reduce the signs and symptoms of allergic rhinitis (hayfever). Subjects' participation in the study will last approximately 4 to 6 weeks, and each of three study visits during that time will last a few hours. Subjects will be required to h...
What is the current status of trial NCT01500629?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2012-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01500629?
The interventions under investigation include: C-1266-7 (DEVICE), C-1266-6 (placebo) (DEVICE).
Who is sponsoring clinical trial NCT01500629?
This trial is sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.